Semafore’s pi3 kinase inhibitor sf1126 is a vascular targeted conjugate in phase i clinical trials in solid tumors and multiple myeloma
April 15th, 2008 by 
admin SAN DIEGO, Apr 14, 2008 /PRNewswire/ — Semafore
Pharmaceuticals Inc. declared today on the occurrence of a poster
presentation at the 2008 AACR Annual Meeting that its
integrin-targeted PI3 kinase inhibitor, SF1126, was shown to cause
significant… (Source: Drugs.com - Clinical Trials)
Tags: Annual Meeting, April, Drugs, San Diego
Posted in Cancer | 